Europe Influenza Vaccines Market 2019-2028

MARKET OUTLOOK

This report states that the influenza vaccines market in Europe would surge at a CAGR of 6.16% over the projected period 2019-2028. Germany, Spain, France, Italy, the United Kingdom, Russia and the Rest of Europe comprise the influenza vaccines market in Europe.
The influenza vaccines market in Europe is experiencing considerable growth due to the rising government funding and the increasing expenditure by the key market players in the region. A total of 86% of the vaccines produced in the region are exported over the world, of which more than 50% is exported to humanitarian groups like PAHO (Pan American Health Organization) and UNICEF (United Nations Children’s Fund). Besides, the region spends about $2.49 billion annually on the research & development activities of the vaccines. All these factors are supposed to create a positive impact on regional market growth.

The high prevalence of influenza in the European countries is set to surge the immunization rate, which is likely to drive the growth of the influenza vaccines market during the forecasted period. As per the ECDC (European Centre for Disease Prevention and Control) data, seasonal influenza causes about 40 to 50 million symptomatic cases and around 15,000 to 70,000 deaths in Europe every year. These factors indicate an increased demand for the studied market in the region.

COMPETITIVE OUTLOOK

Some of the players operating in the influenza vaccines market are CSL Limited, Sanofi, Abbott, GlaxoSmithKline Plc and BioDiem.

1. Europe Influenza Vaccines Market - Summary

2. Industry Outlook

2.1. Market Definition
2.2. Key Insights
2.2.1. Quadrivalent is the Dominant Type of Influenza Vaccine
2.2.2. Injection is Fastest-Growing Delivery Mode
2.2.3. Cell-Based Technology is Rapidly Growing Technology in the Market
2.2.4. Adult Age Group is Majorly Contributing in the Market
2.3. Porter's Five Force Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitute
2.3.3. Bargaining Power of Suppliers
2.3.4. Bargaining Power of Buyers
2.3.5. Intensity of Competitive Rivalry
2.4. Market Attractiveness Index
2.5. Vendor Scorecard
2.6. Market Drivers
2.6.1. Advancement in Technology
2.6.2. Initiatives Taken Up by the Government
2.7. Market Restraints
2.7.1. High Cost of Development
2.8. Market Opportunities
2.8.1. Growth in the Cases of Influenza
2.9. Market Challenges
2.9.1. Complex Development Process

3. Influenza Vaccines Market Outlook - by Type

3.1. Quadrivalent Vaccine
3.2. Trivalent Vaccine

4. Influenza Vaccines Market Outlook - by Technology

4.1. Egg-Based Technology
4.2. Cell-Based Technology

5. Influenza Vaccines Market Outlook - by Age Group

5.1. Pediatric Age Group
5.2. Adult Age Group

6. Influenza Vaccines Market Outlook - by Delivery Mode

6.1. Injection
6.2. Nasal Spray

7. Influenza Vaccines Market – Europe

7.1. United Kingdom
7.2. Germany
7.3. France
7.4. Spain
7.5. Italy
7.6. Russia
7.7. Rest of Europe

8. Competitive Landscape

8.1. Merck Sharp & Dohme Corp
8.2. Novartis AG
8.3. Pfizer Inc
8.4. Sanofi
8.5. Biodiem
8.6. Emergent Biosolutions Inc
8.7. F. Hoffmann-La Roche Ltd
8.8. GlaxoSmithKline plc
8.9. Abbott
8.10. CSL Limited

9. Research Methodology & Scope

9.1. Research Scope & Deliverables
9.1.1. Objectives of Study
9.1.2. Scope of Study
9.2. Sources of Data
9.2.1. Primary Data Sources
9.2.2. Secondary Data Sources
9.3. Research Methodology
9.3.1. Evaluation of Proposed Market
9.3.2. Identification of Data Sources
9.3.3. Assessment of Market Determinants
9.3.4. Data Collection
9.3.5. Data Validation & Analysis

List of Tables

Table 1: Europe Influenza Vaccines Market, by Country, 2019-2028 (In $ Million)
Table 2: Vendor Scorecard
Table 3: Europe Influenza Vaccines Market, by Type, 2019-2028 (In $ Million)
Table 4: Europe Influenza Vaccines Market, by Technology, 2019-2028 (In $ Million)
Table 5: Europe Influenza Vaccines Market, by Age Group, 2019-2028 (In $ Million)
Table 6: Europe Influenza Vaccines Market, by Delivery Mode, 2019-2028 (In $ Million)
Table 7: Europe Influenza Vaccines Market, by Country, 2019-2028 (In $ Million)

List of Figures

Figure 1: Europe Influenza Vaccines Market, by Source, 2019 & 2028 (In %)
Figure 2: Europe Quadrivalent Influenza Vaccines Market, 2019-2028 (In $ Million)
Figure 3: Europe Injection Delivery Model Market, 2019-2028 (In $ Million)
Figure 4: Europe Cell-Based Technology Market, 2019-2028 (In $ Million)
Figure 5: Europe Adult Age Group Market, 2019-2028 (In $ Million)
Figure 6: Porter's Five Force Analysis
Figure 7: Market Attractiveness Index
Figure 8: Europe Influenza Vaccines Market, by Quadrivalent Vaccine, 2019-2028 (In $ Million)
Figure 9: Europe Influenza Vaccines Market, by Trivalent Vaccines, 2019-2028 (In $ Million)
Figure 10: Europe Influenza Vaccines Market, by Egg-Based Technology, 2019-2028 (In $ Million)
Figure 11: Europe Influenza Vaccines Market, by Cell-Based Technology, 2019-2028 (In $ Million)
Figure 12: Europe Influenza Vaccines Market, by Pediatric Age Group, 2019-2028 (In $ Million)
Figure 13: Europe Influenza Vaccines Market, by Adult Age Group, 2019-2028 (In $ Million)
Figure 14: Europe Influenza Vaccines Market, by Injection, 2019-2028 (In $ Million)
Figure 15: Europe Influenza Vaccines Market, by Nasal Spray, 2019-2028 (In $ Million)
Figure 16: Europe Influenza Vaccines Market, Regional Outlook, 2019 & 2028 (In %)
Figure 17: United Kingdom Influenza Vaccines Market, 2019-2028 (In $ Million)
Figure 18: Germany Influenza Vaccines Market, 2019-2028 (In $ Million)
Figure 19: France Influenza Vaccines Market, 2019-2028 (In $ Million)
Figure 20: Spain Influenza Vaccines Market, 2019-2028 (In $ Million)
Figure 21: Italy Influenza Vaccines Market, 2019-2028 (In $ Million)
Figure 22: Russia Influenza Vaccines Market, 2019-2028 (In $ Million)
Figure 23: Rest of Europe Influenza Vaccines Market, 2019-2028 (In $ Million)